... u doba Covida
Igrom slučaja ja nešto pažljivije pratim samo Covid19 u UK sada. Za vreme prvog talasa sam čitao skoro sve na šta sam nailazio.
U UK nema drugog talasa - npr u Londonu ga baš nema, dok u ostacima zemlje imamo "tail-ends". Virus je, po svemu sudeći, ulgavnom jedno-sezonski.
Tako, nije mi namera da potcenjujem opasnosti u još mnogim krajevima i po UK, ostatku Evrope i dalje, sada, i do nekog doba sledeće godine.
Istovremeno, MSM medijska drama je skoro pa neverovatna, iako je veliki deo populacije jako sumnjičav.
Savetnici koje je država izabrala, iz naučnih pa širih krugova, pod zajedničkim imenom "SAGE" su nesposobni do imbecilnosti - ovi gore ruski farmeri su sposobniji od njih. Nepotrebno je reći da u UK, kao i svuda, ima jako mnogo inteligentnih i dobronamernih naučnika i menadžera.
I dalje više verujem u tu priču o nesposobnosti nego u konspiraciju, iako ovde dole dajem primer vanrednog stručnjaka čiji su YouTube clip sklonili nekoliko sati posle objavljivanja. Tako, clip dolazi na pomalo user-unfriendly način, pod zaštitničkim okriljem tu i tamo block-chain tehnologije, ubačen blizu polovine članka kako se klikne na link.
I stranica je informativna, ko već ne zna sve ovo, nego je interesantno prosto videti smirenog stručnjaka koji objašnjava šta se dešava.
Pa tako, još samo nešto o autoru:
"...Dr. Michael Yeadon is an Allergy & Respiratory Therapeutic Area expert with 23 years in the pharmaceutical industry. He trained as a biochemist and pharmacologist, obtaining his PhD from the University of Surrey (UK) in 1988.
Dr. Yeadon then worked at the Wellcome Research Labs with Salvador Moncada with a research focus on airway hyper-responsiveness and effects of pollutants including ozone and working in drug discovery of 5-LO, COX, PAF, NO and lung inflammation. With colleagues, he was the first to detect exhaled NO in animals and later to induce NOS in lung via allergic triggers.
Joining Pfizer in 1995, he was responsible for the growth and portfolio delivery of the Allergy & Respiratory pipeline within the company. He was responsible for target selection and the progress into humans of new molecules, leading teams of up to 200 staff across all disciplines and won an Achievement Award for productivity in 2008.
Under his leadership the research unit invented oral and inhaled NCEs which delivered multiple positive clinical proofs of concept in asthma, allergic rhinitis and COPD. He led productive collaborations such as with Rigel Pharmaceuticals (SYK inhibitors) and was involved in the licensing of Spiriva and acquisition of the Meridica (inhaler device) company.
Dr. Yeadon has published over 40 original research articles and now consults and partners with a number of biotechnology companies. Before working with Apellis, Dr. Yeadon was VP and Chief Scientific Officer (Allergy & Respiratory Research) with Pfizer..."